A framework for further investigation into Ova’s potential therapeutic role as a novel small molecular inhibitor of STAT3, which is constitutively activated in most malignancies, including oral cancer, has been established by the replication of its anticancer and CDDP-enhancing activities in preclinical in vivo oral cancer models [77]. The gene discussed is STAT3; the disease is lip and oral cavity carcinoma.